ATC Group: M01AH05 Etoricoxib

Anatomical Therapeutic Chemical Classification System

Hierarchical position in ATC classification

Level
Code
Title
1
Musculo-skeletal system
2
Antiinflammatory and antirheumatic products
3
Antiinflammatory and antirheumatic products, non-steroids
4
Coxibs
5
M01AH05
Etoricoxib

Active ingredients

Active Ingredient
Description

Etoricoxib is an oral, selective cyclo-oxygenase-2 (COX-2) inhibitor within the clinical dose range. Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function). It may also play a role in ulcer healing. COX-2 has been identified in tissue around gastric ulcers in man but its relevance to ulcer healing has not been established.

Medicines in this ATC group

Drug
Countries

Hong Kong

Austria Brazil Cyprus Finland France ...

New Zealand

Lithuania

Singapore

Lithuania

Hong Kong

Poland

Lithuania

Germany

Hong Kong

Hong Kong

Hong Kong

Italy Singapore

Hong Kong

Brazil

Hong Kong

Hong Kong

Cyprus

Lithuania

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Poland

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)
DE